23 Sep Non–TNF-Targeted Biologic Found Superior to Second Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF Drug
MedicalResearch.com Interview with:
Jacques-Eric Gottenberg, MD, PhD
Department of Rheumatology
National Reference Center for Systemic Autoimmune Diseases
Strasbourg University Hospital, Université de Strasbourg
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: There is no recommendation for the choice of the second biologic in patients with rheumatoid arthritis and insufficient response to a first anti-TNF, which is a common situation in our daily practice (approximately one third of patients treated with anti-TNF). We therefore conducted the first randomized trial to date to investigate the best strategy in such a setting.
MedicalResearch.com: What should readers take away from your report?
Response: We demonstrated a superior effectiveness of non-TNF targeted biologics (abatacept, rituximab or tocilizumab) compared to a second anti-TNF medication.
MedicalResearch.com: What recommendations do you have for future research as a result of this study?
Response: Future research should now compare the non-TNF targeted biologic by implementing head to head randomized controlled trials (for example abatacept versus tocilizumab).
MedicalResearch.com: Thank you for your contribution to the MedicalResearch.com community.
Gottenberg J, Brocq O, Perdriger A, et al. Non–TNF-Targeted Biologic vs a Second Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF Drug: A Randomized Clinical Trial. JAMA. 2016;316(11):1172-1180. doi:10.1001/jama.2016.13512.
Note: Content is Not intended as medical advice. Please consult your health care provider regarding your specific medical condition and questions.
More Medical Research Interviews on MedicalResearch.com